Sanofi Acquires Blueprint Medicines in $9.1B Deal, Bolstering Rare Immunology Pipeline

Paris and Cambridge, MA, June 2, 2025 (GlobeNewswire) -- Sanofi will acquire Blueprint Medicines for approximately $9.1 billion, adding a rare immunology therapy and a promising pipeline to its portfolio. The deal includes Blueprint’s Ayvakit, the sole approved treatment for systemic mastocytosis, alongside emerging assets like elenestinib and BLU-808. This acquisition marks a significant expansion of Sanofi’s immunology and rare disease presence, expected to drive both innovation and revenue growth.

Read full article here.